| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8833827 | Journal of the American College of Surgeons | 2018 | 26 Pages |
Abstract
Pasireotide did not reduce the incidence or severity of pancreatic fistulas after pancreaticoduodenectomy, but was associated with a decrease in postoperative bleeding/anemia. A multicenter randomized trial is needed to accurately define the role of pasireotide in the postoperative management of pancreaticoduodenectomy patients.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Ismael MD, Ryan C. MD, FACS, Cheryl A. PA-C, Gregory MA, Timothy A. PharmD, J Bart MD, Chet W. MD, Maria B. MD, MBA, William C. MD, FACS, Steven M. MD, FACS, William G. MD, FACS, Dominic E. MD, MPHS,